# CASI Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/CASI Pharmaceuticals, Inc.). ## Overview CASI Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. The company’s work spans clinical development, regulatory filings, and the advancement of antibody-based therapies from early-stage research toward human studies. ## Products & services • CID-103 anti-CD38 monoclonal antibody • Clinical development for transplant rejection • Clinical development for autoimmune diseases • Protein formulation development for subcutaneous injection • Regulatory submissions for clinical trials - **CID-103 clinical development** (100%) — Development of the anti-CD38 antibody CID-103 for immunology and transplant indications. - **Regulatory and clinical operations** (0%) — Trial planning, submissions, and execution activities supporting development programs. - **Formulation development** (0%) — Work on stable, high-concentration protein solutions for subcutaneous delivery. - CID-103 anti-CD38 monoclonal antibody - Clinical development for transplant rejection - Clinical development for autoimmune diseases - Protein formulation for subcutaneous injection - Regulatory submissions and trial support ## Customers CASI’s direct commercial customers are limited because the company is primarily a development-stage biopharmaceutical business. Its economic value is tied mainly to patients, clinicians, hospitals, and transplant centers that may eventually use CID-103, as well as regulators and research partners involved in clinical development. - **Transplant rejection patients** (primary) — Patients with chronic active renal allograft antibody-mediated rejection who may benefit from CID-103 if developed successfully. - **Autoimmune disease patients** (primary) — Patients with immune thrombocytopenia and related autoimmune disorders targeted by the anti-CD38 program. - **Hospitals and transplant centers** (secondary) — Clinical sites that enroll and treat patients in studies and would later administer the therapy in practice. - **Regulators and ethics committees** (secondary) — Authorities that review CTA and IND filings and determine whether clinical trials can proceed. - **Future partners** (emerging) — Potential collaborators or licensees that may support development, manufacturing, or commercialization. - Patients with transplant rejection or autoimmune disease - Hospitals and transplant centers treating refractory cases - Clinicians participating in clinical trials - Regulators reviewing CTA/IND submissions - Potential future license or development partners ## Geography CASI is operationally tied to the United States and China through its clinical and regulatory activities. The company’s principal executive office is in Beijing, while its product development program includes a U.S. IND and a Chinese CTA for CID-103. - **United States** (50%) — Clinical and regulatory program activity includes a U.S. IND - **China** (50%) — Principal office and Chinese CTA activity - Principal executive office in Beijing, China - Clinical development includes U.S. and China filings - Regulatory exposure spans FDA and Chinese authorities - Future commercialization could depend on multiple markets ## Strategy CASI’s strategy centers on advancing CID-103 through early clinical development and building evidence for its transplant and autoimmune indications. A second priority is improving drug formulation for subcutaneous administration, which could support usability and differentiation if development succeeds. - **Advance CID-103 clinical trials** (short-term) — Clinical data is the main value driver for a development-stage biotech company. - **Expand indication set** (medium-term) — Multiple indications can improve the asset’s commercial potential and reduce single-program risk. - **Improve formulation and delivery** (medium-term) — A stable subcutaneous product could improve patient convenience and product differentiation. - Advance CID-103 through Phase 1/2 clinical development - Build proof-of-concept in transplant rejection and ITP - Differentiate through anti-CD38 biology and epitope targeting - Develop subcutaneous formulation capabilities - Maintain regulatory progress in U.S. and China ## Risks CASI faces classic clinical-stage biotech risks, including trial failure, safety concerns, and regulatory delays, because its value depends heavily on a single lead asset. The company also has execution risk tied to cross-border development and market access, plus financial and listing-related risks that can limit trading liquidity and investor confidence. - **Clinical development failure** [critical] — The company’s value is concentrated in CID-103, so disappointing efficacy or safety data could materially impair prospects. - **Regulatory delay or non-approval** [high] — CTA/IND approvals and later submissions are required to continue development and eventually commercialize the asset. - **Program concentration** [high] — A single lead asset creates limited diversification if the program underperforms or is terminated. - **Capital markets and listing risk** [medium] — Biotech development requires ongoing funding and market access, and trading venue changes can affect liquidity. - Clinical failure risk for CID-103 - Safety or efficacy issues in human studies - Regulatory delays in U.S. or China - Dependence on a single lead program - Capital market and listing-related uncertainty ## Accounting As a development-stage biopharmaceutical company, CASI’s reported results are shaped by research and development spending, clinical program timing, and foreign currency effects. Any future collaboration or licensing arrangements would also raise revenue-recognition judgments, while asset valuation and impairment assessments remain important because the business is centered on a narrow set of development assets. - **Research and development expense** — Operating loss and cash burn - **Foreign exchange** — Other income/expense - **Revenue recognition** — Reported revenue and deferred revenue - **Impairment and valuation** — Balance sheet and earnings - R&D expense timing affects reported operating loss - Clinical-stage costs can be uneven quarter to quarter - Foreign exchange can move reported results - Future license revenue may require IFRS 15 judgment - Asset impairment risk is tied to pipeline value --- *Last updated: 2026-09-28T11:58:02.946213+00:00*